[HTML][HTML] Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
O Le Saux, I Ray-Coquard, SI Labidi-Galy - Seminars in cancer biology, 2021 - Elsevier
Platinum resistant ovarian cancer, usually defined as progression occurring within 6 months
after completing platinum-based therapy, is a heterogeneous disease with poor prognosis …
after completing platinum-based therapy, is a heterogeneous disease with poor prognosis …
[HTML][HTML] Three-dimensional modelling of ovarian cancer: From cell lines to organoids for discovery and personalized medicine
C Yee, KA Dickson, MN Muntasir, Y Ma… - … in Bioengineering and …, 2022 - frontiersin.org
Ovarian cancer has the highest mortality of all of the gynecological malignancies. There are
several distinct histotypes of this malignancy characterized by specific molecular events and …
several distinct histotypes of this malignancy characterized by specific molecular events and …
Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application
A Ciucci, M Buttarelli, A Fagotti, G Scambia… - Cellular and Molecular …, 2022 - Springer
Despite many improvements in ovarian cancer diagnosis and treatment, until now,
conventional chemotherapy and new biological drugs have not been shown to cure the …
conventional chemotherapy and new biological drugs have not been shown to cure the …
Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer
T Samec, KL Alatise, J Boulos, S Gilmore… - … Therapy-Nucleic Acids, 2022 - cell.com
Ovarian cancer has shown little improvement in survival among advanced-stage patients
over the past decade. Current treatment strategies have been largely unsuccessful in …
over the past decade. Current treatment strategies have been largely unsuccessful in …
Biomaterial considerations for ovarian cancer models
M Kramer, A Criswell, MK Sewell-Loftin - Frontiers in Materials, 2023 - frontiersin.org
Ovarian cancer is the 5th most common and the deadliest gynecological cancer, with a 5-
year survival rate of less than 50 percent. Most deaths due to ovarian cancer are caused by …
year survival rate of less than 50 percent. Most deaths due to ovarian cancer are caused by …
Fibronectin and periostin as prognostic markers in ovarian cancer
KA Kujawa, E Zembala-Nożyńska, AJ Cortez, T Kujawa… - Cells, 2020 - mdpi.com
Previously, based on a DNA microarray experiment, we identified a 96-gene prognostic
signature associated with the shorter survival of ovarian cancer patients. We hypothesized …
signature associated with the shorter survival of ovarian cancer patients. We hypothesized …
In high‐grade ovarian carcinoma, platinum‐sensitive tumor recurrence and acquired‐resistance derive from quiescent residual cancer cells that overexpress CRYAB …
S Du Manoir, H Delpech, B Orsetti… - The Journal of …, 2022 - Wiley Online Library
Most high‐grade ovarian carcinomas (HGOCs) are sensitive to carboplatin (CBP)‐based
chemotherapy but frequently recur within 24 months. Recurrent tumors remain CBP …
chemotherapy but frequently recur within 24 months. Recurrent tumors remain CBP …
[HTML][HTML] Experimental models for ovarian cancer research
Among all gynecological malignancies, ovarian cancer (OC) accounts for the highest
mortality rate due to high therapeutic resistance, prolonged latency and a lack of effective …
mortality rate due to high therapeutic resistance, prolonged latency and a lack of effective …
Modeling the tumor microenvironment of ovarian cancer: the application of self-assembling biomaterials
AK Mendoza-Martinez, D Loessner, A Mata… - Cancers, 2021 - mdpi.com
Simple Summary The tumor-surrounding niche comprises not only cancer cells but also
stromal cells, signaling molecules, secreted factors and the extracellular matrix. This niche …
stromal cells, signaling molecules, secreted factors and the extracellular matrix. This niche …
Patient-derived xenografts are a reliable preclinical model for the personalized treatment of epithelial ovarian cancer
J Chen, Y Jin, S Li, C Qiao, X Peng, Y Li, Y Gu… - Frontiers in …, 2021 - frontiersin.org
To generate robust patient-derived xenograft (PDX) models for epithelial ovarian cancer
(EOC), analyze the resemblance of PDX models to the original tumors, and explore factors …
(EOC), analyze the resemblance of PDX models to the original tumors, and explore factors …